PTO/SB/08a (03-08)
Approved for use through 05/31/2008 OMB 0651-0201
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10765943		
	Filing Date		2004-01-29		
NFORMATION DISCLOSURE	First Named Inventor YASU		SUYUKI NUMAJIRI		
STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit		1634		
Not for submission under 57 Of R 1.337	Examiner Name AMAN		MANDA MARIE SHAW		
	Attorney Docket Numb	er	00862.023438		

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [Date	Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Relev		Lines where ges or Relev	
	1	20020049682	A1	2002-04	1-25	YАМАМОТО В	ET AL.				
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d butto			
				FOREIG	SN PA1	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document		where Rel	or Relevant	т.
	1	2001-147231	JP		A	2001-05-29	HITACHI MAXELL	LTD.			×
	2	2002-074316	JP		A	2002-03-15	CANON KABUSHI KAISHA	a			
	3	2001-195366	JP		A	2001-07-19	OKI ELECTRIC INI	D. CO.			×

| INFORMATION DISCLOSURE | Application Number | 10755943 | Filing Date | 2004-01-29 | Filing Date | 20

	4	2002-073572	JP	A	2002-03-12	CANON KABUSHIKI KAISHA		
If you wish	h to a	dd additional Foreign F	atent Document	citation	information pl	lease click the Add buttor	Add	
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (look, magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Τs	
	1							
If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE								
Examiner	Signa	ture				Date Considered		

See Kind Codes of USPTO Platent Documents at Invest (ISPTO, DOLL) or IMPER 961.04. 2 Enter office that Issued the document, by the Involved ow (IMPO, Standard S13.) 3 For Laplanese patient documents, the ordication of the year of the region of the Emporer many precise the serial runber of the patient document.

Yard of Coursent by the appropriate symbols as indicated on the document under WIPO Standard S11.6 if possible. **Applicant is to place a check mark here if Empirish tarquages transitions in statched.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10765943		
Filing Date		2004-01-29		
First Named Inventor	YASUYUKI NUMAJIRI			
Art Unit		1634		
Examiner Name	AMAN	MANDA MARIE SHAW		
Attorney Docket Numb	ec	00862 023438		

CERTIFICATION STATEMENT

Please see	37	CFR	1 97	and	1 98 to	make th	e anno	nnista e	alaction/s	۰۱۰

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Jason M. Okun/	Date (YYYY-MM-DD)	2008-05-28
Name/Print	Jason M. Okun	Registration Number	48512

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.